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Abstract: In the current study, the metabolism of two
novel psychoactive substances (NPSs), mephedrone
and methoxetamine (MXE), was studied in vitro in pig
liver microsomes to determine potential metabolites by
liquid chromatography-mass spectrometry (LC-MS). Later,
in vitro studies were performed using HepaRG™ cells to
determine the human metabolites of these drugs using
gas chromatography-mass spectrometry (GC-MS). The
aim of the study was to detect metabolites from the meta-
bolic mixture in the human cell lines using GC-MS, since
this is a more readily available technique within forensic
laboratories. Microsomes were prepared through a con-
ventional ultracentrifugation method and incubated under
optimized conditions with the drugs for 3 h. Subsequently,
the samples were investigated using LC-MS. A similar
methodology was then applied in the HepaRG™ cells,
and the GC-MS conditions were optimized using N,O-bis
(trimethylsilyl)trifluoroacetamide as a derivatization agent.
The analysis showed two molecules from a successful
in vitro metabolism, namely, hydroxytoly-mephedrone and
nor-dihydro mephedrone. For MXE, two metabolites are
presented produced by theO-demethylation and reduction
of the ketone moiety to the corresponding alcohol, respec-
tively. Using the human HepaRG™ cells, only nor-dihydro
mephedrone could be identified by GC-MS. Since hydro-
xytoly-mephedrone and theMXEmetabolites are more polar,
it is suggested that GC-MS even with derivatization may not
be suitable. In addition, cytotoxicity was studied utilizing
HepaRG™ cell lines. The drugs show cytotoxic effects
causing in vitro cell death, within the specified range of
EC50 0.3211 mM (79 μg/mL) and 0.6297 mM (111 μg/mL)
for mephedrone and MXE, respectively. These drugs
were able to cause 73–84% cell death.
Keywords: in vitro metabolism, mephedrone, methoxet-
amine, cytotoxicity, mass spectrometry, EC50
1 Introduction
In recent years, many designer drugs have appeared on
the recreational drug market, where most of them are
sold as “legal highs” by street suppliers or via the
Internet [1]. “Designer drugs” are those produced by per-
forming minor alterations to one or more functional
groups of a known chemical with specific pharmacolo-
gical activity to avoid the legal regulations and to pro-
duce more effective substances [2].
The therapeutic and toxicological profiles of the
designer drugs are not systemically studied by pharma-
ceutical companies and regulatory authorities as in the
case of pharmaceutical drugs. Therefore, the analysis
of designer drugs and their metabolites has recently
received increasing interest from academic and govern-
mental researchers [3]. Metabolic studies with regard to
the toxicological profiles of designer drugs are one of the
most important research areas. The limited opportunities
to obtain reference standards for the metabolites of novel
psychoactive substances (NPSs) make in vitro production
of these metabolites a valuable tool to develop analytical
methods for the detection of NPS and their metabolites.
However, caution needs to be added as the conclusions
from these studies might not be directly applicable to
humans. As Tice et al. suggested [4] the following rea-
sons to observe caution: (i) problems to include xeno-
biotic metabolism into in vitro assays, (ii) problems to
follow interactions between different cell types, (iii) diffi-
culties in extrapolating the results from in vivo doses to in
vitro concentrations, and (iv) problems to track long-term
exposures in vitro.
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Since mephedrone was described as one of the first
legal highs in 2007, it has been detected in many toxico-
logical samples [5–8]. Due to the fatalities reported after
the consumption of mephedrone, it was added to the UK
Misuse of Drugs Act 1971 in 2010 before the Psychoactive
Substance Bill was passed in the UK in 2015 [9]. No much
data are available about the clinical or toxic effects of
mephedrone, and it has never been licensed as a medi-
cine since its first appearance in the illicit drug market in
2007. Other countries have followed a similar approach;
and it is now banned, but in others it still remains as a
legal substance. Although being a popular drug, limited
data are still found on the metabolism of mephedrone in
the literature [10–12]. More recent work from M. Farré
et al. has opened the door to a greater understanding of
the pharmacokinetics [13,14], in vivo human metabolism
[15], pharmacology [16,17] and clinical studies [18].
Methoxetamine (MXE) 2-(ethylamino)-2-(3-methoxy-
phenyl)cyclohexanone is a newer, synthetic, psychoac-
tive drug derived from ketamine [12,19]. It is believed that
MXE is being used as a ketamine substitute, owing to its
ability to produce comparable hallucinogenic and disso-
ciative effects [20]. Initially, MXE was designed in part to
prevent the urotoxicity associated with ketamine and to
be tested as an antidepressant [19,20]. However, since its
debut on the Internet in 2010, it has become a popular
recreational drug especially among adolescents. Indeed,
there has been an increase in the number of reports
regarding the abuse of MXE by humans, which resulted
in serious or even fatal outcomes [21,22]. Accordingly,
MXE was included in the list of new psychoactive sub-
stances of the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA), which was categorized as a
ketamine derivative [20]. In April 2012, MXE was placed
under temporary class drug control in the UK and is now
banned through the Psychoactive Substance Bill (2015).
Some information regarding the toxicological and clinical
data can be found in literature for MXE, with limited
metabolic studies being available [19,23,24].
Even though these compounds are now banned in
the UK and other countries, the limited information on
their metabolism may still make it hard for investigations
and emergency services in the UK or other countries
without a blanket ban. The increasing reported abuse of
NPSs including mephedrone and MXE, combined with
restricted information about their toxicological profile,
has created a requirement for the production and identi-
fication of their metabolites.
Therefore, this research will focus on the initial
screening of the metabolites. Considering the limitations,
in vitro approaches are preferred methods for studying
the metabolism of designer drugs when ethical consid-
erations are in place. Additionally, in vitro drug metabo-
lism methods are generally easier and more rapid to
apply compared to in vivo approaches. In vitro metabo-
lism using microsomes, an approach to study the meta-
bolic profile of new emerging drugs, is widely used in
the pharmaceutical industry. Microsomes are vesicle-
like artefacts that are made from portions of endoplasmic
reticulum after disintegrating eukaryotic cells; they can
be concentrated and separated from other cellular debris
by differential centrifugation [25]. The pig liver has been
used as an animal model for drug metabolic studies
because of its similarity in size and physiology with
that of humans and the similar distribution of different
families of CYP450 enzymes between pigs and humans
[26]. It is therefore a good screening tool to identify
potential metabolites.
Also, the use of in vitro human cell lines, such as
HepaRG™ cells, to identify any metabolites needs to be
considered in studies as animal models may not predict
the exact human metabolism. The aim of the study was
to detect metabolites from the metabolic mixture in
the human cell lines using a gas chromatography–mass
spectrometry (GC-MS), since this is a more readily avail-
able technique within forensic laboratories. Also, a
comparison with an animal model using liquid chroma-
tography–mass spectrometry (LC-MS) is included.
Consequently, this study tries to identify potential meta-
bolites of MXE and mephedrone, which could be easily
analysed in commercial laboratories. To the authors’
knowledge, human HepaRG™ cells have not been used
to identify any metabolites for MXE or mephedrone.
2 Materials and methods
Mephedrone and MXE were purchased legally from web-
based companies before they were declared illegal and
stored under the appropriate drug license after the ban.
The structure and purity of the purchased drugs were
confirmed by Fourier transform infrared spectroscopy
(FTIR) and MS.
Tris–Cl 1 M stock solution, sodium pyrophosphate
and EDTA, nicotinamide adenine dinucleotide phosphate
(NADP), glucose-6-phosphate dehydrogenase enzyme
(G6PD) and glucose-6-phosphate (G6P), trypan blue,
and phosphate buffer (pH = 7) solution were all of analy-
tical grade (Sigma, UK). Potassium chloride, monobasic
sodium phosphate, dibasic sodium phosphate, magne-
sium chloride, methanol, and formic acid (99%) were
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all of analytical grade (Fisher, UK). Deionized water
(resistance = 15 MΩ) was used in all preparations and,
where needed, filtered, and degassed prior to use. For
derivatization, N,O-bis(trimethylsilyl)trifluoroacetamide
(BSTFA was purchased from Supelco (UK).
Select NPS were studied using pooled human suspen-
sion hepatocytes, namely, primary human hepatocytes,
cryopreserved hepatocytes recovery medium (catalogue
number: CM7000), and primary human hepatocytes main-
tenance supplement pack (catalogue number: CM4000)
containing dexamethasone and COCKTAIL-B solution
were all from Gibco (UK).
For the study of selected NPS using HepaRG™:
HepaRG™ cryopreserved cell line (catalogue number:
HPRGC10), William’s E Medium-no phenol red (catalogue
number: A12176-01), HepaRG™ Thaw, Plate, & General
Purpose Medium Supplement (catalogue number: HPRG770),
HepaRG Tox Medium Supplement (catalogue number:
HPRG730), HepaRG Maintenance/Metabolism Medium
Supplement (catalogue number: HPRG720), and GlutaMAX™-I
Supplement (catalogue number: A12860-01) were all
from Gibco (UK).
Fresh pig liver was obtained from a local abattoir.
2.1 Preparation of buffers and solutions
The NADPH-regenerating system (30mM G6P, 5 U/mL
G6PD, 10mM NADP, and 30mM MgCl2) was freshly pre-
pared every day before incubation. The homogenizing
buffer consisted of 0.1 M Tris HCl, 10 mM EDTA, and
150 mM KCl; the microsome-preservation buffer of
0.05 M Tris HCl, 10 mM EDTA and 20% (v/v) glycerol,
and the pyrophosphate buffer of 0.1 M Na-pyrophosphate
and 10mM EDTA, with the final pH values adjusted to 7.4
using sodium chloride or hydrochloric acid.
HepaRG™ Thaw, Plate, & General Purpose Medium
and HepaRG Tox Medium were freshly and aseptically
prepared by adding 1 mL of GlutaMAX and 14mL of
HepaRG™ Thaw, Plate, & General Purpose Medium or
HepaRG™ Tox Medium Supplement to 100mL of William’s
Medium E.
HepaRG™ Maintenance/Metabolism Medium was
freshly and aseptically prepared by adding 1 mL of
GlutaMAX and 16mL of HepaRG™ Maintenance/Metabolism
Medium Supplement to 100mL of William’s Medium E.
Master stock solutions of mephedrone and MXE were
prepared in HepaRG™ Thaw, Plate, & General Purpose
Working Medium and were at least 10 times more con-
centrated than the highest concentration tested (i.e.
1.6 × 102 mM). All stock solutions were preserved at
−20°C for later use.
Pooled human hepatocyte stocks were stored and
maintained under liquid nitrogen (−196°C) until needed.
The cryopreserved pooled hepatocyte vial was thawed
and re-suspended into 10mL media to a final concentra-
tion of 1 × 106 cells/mL (10 × 106 total cells count). Cell
viability was estimated to be greater than 85% using
trypan blue exclusion test. Trypan blue test solution
test was prepared at 0.4% in phosphate-buffered solution
and 0.1 mL added to 1 mL cell solution and examined
under microscope.
2.2 Isolation and incubation of liver
microsomes
Liver microsomes were isolated following previously
published protocols with minor modifications [23,27,28].
Briefly, liver was freshly obtained, washed with homoge-
nizing buffer at pH 7, and sliced into 4 g portions. The
sliced portions were further cut into small pieces using a
surgical blade, broken apart with 3 volumes of ice-cold
homogenizing buffer using a handheld bio-homogenizer,
and homogenized using Teflon mortar and pestle. The
homogenate was centrifuged for 15 min at 12,500 × g at
4°C, in an Allegra X-22 from Beckman Coulter™ (UK),
and the supernatant was divided into two portions, of
which one was stored as S9 fraction and the other was
further ultracentrifuged for 45 min at 76,800 × g at 4°C in
a Mikro 20 Hettich Zentrefugen Microcentrifuge (USA).
The pellet was re-suspended with 2 volumes of ice-cold
pyrophosphate buffer, further homogenized, and ultra-
centrifuged for 70min at 76,800 × g at 4°C; the superna-
tant was discarded and the formed pellet was suspended
with 3 volumes of microsome-preservation buffer, further
homogenized, and stored at −80°C in a Binder UF V 500
ULT Freezer until needed.
Five 1.5-mL microcentrifuge tubes for each test com-
pound were prepared; five 1.5-mL microcentrifuge tubes
included duplicate tubes for both 0 time and 3 h, and one
tube for the negative control. Each tube contained 375 µL
0.1 M phosphate buffer (pH 7.4), pre-warmed to 37°C,
50 µL NADPH-regeneration system, and 50 µL of 10-fold
test compound stock solution (100 µg/mL). The mixture
was then incubated in a water bath for 5 min at 37°C. For
the negative control, 50 µL NADPH-regeneration systems
were replaced by 50 µL 0.1 M phosphate buffer. Prepared
microsomes or S9 fractions were thawed and diluted to
10mg/L and 25 µL added to each tube. Samples were
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mixed and incubated at 37°C in a shaking water bath.
The process was terminated by adding 250 µL ice-cold
methanol at 0 time for two of the positive test tubes
and at 3 h for the other two positive tubes and the nega-
tive tube sample. Sample tubes were centrifuged for
10 min at 13,000 × g. The supernatant was then filtered
through 0.45 µm filters (Sartorius, Germany) and 5 µL
injected onto the LC-MS system (Agilent, US).
LC-MS analyses were performed with an Agilent 6310
LC-MS ion trap system equipped with electrospray ioni-
zation. Data acquisition was performed using DataAnalysis
for 6300 Series Ion Trap LC-MS version 4.0 © software,
and the scans were performed at a scan range between
40 and 500 amu. The analytes were detected in positive
ionization mode (MS+). The instrument was tuned and
calibrated according to manufacturer’s specifications.
Chromatographic separations were carried out at room
temperature on Agilent Eclipse plus C18, 3.5 µm, 4.6 ×
150 mm. The mobile phase consisted of methanol/water/
formic acid (50/50/0.1, v/v/v), isocratic flow rate of
0.30 mL/min for 10 min. The MS detector was tuned
according to the following conditions: capillary voltage:
3,500 V, capillary intensity: 1 nA, maximum acquisition
time: 200 ms, nebulizer pressure: 30 psi, dry gas flow:
11 L/min, and dry gas temperature: 325°C.
2.3 Preparation and culture of pooled
human hepatocytes
Pooled human hepatocyte stocks were stored and main-
tained under liquid nitrogen (−196°C) until needed. The
cryopreserved pooled hepatocyte vial was thawed and
re-suspended in 10mL media to a final concentration of
1 × 106 cells/mL (10 × 106 total cells count). Cell viability
was estimated to be greater than 85% using trypan blue
exclusion test. Trypan blue test solution test was pre-
pared at 0.4% in phosphate-buffered solution and
0.1 mL added to 1 mL cell solution and examined under
microscope.
The final concentration of 10, 20, 40, 60, 80, and
100 μM of mephedrone and MXE was used for metabolism
studies using pooled human hepatocytes. For each con-
centration, the metabolic profile was studied at 0, 30, 60,
90, and 120min. The metabolic reaction was initiated by
adding 60 μL of the prepared cell suspension and 15 μL of
the 10× stock drug onto 1.5 mL Eppendorf tube and
topped up with media into 150 μL (final drug concentra-
tion = 1×, final cell count > 50 × 103 viable cells). At the
specified time, the reaction was terminated by adding
50 μL 10% DMSO.
2.4 Preparation and culture of
cryopreserved HepaRG™ cells
HepaRG™ cell stocks were stored and maintained under
liquid nitrogen (−196°C) until needed. HepaRG™ vial was
semi-thawed in a water bath at 37°C and the cell suspen-
sion was aseptically transferred into pre-warmed 9mL
of HepaRG™ Thaw, Plate, & General Purpose Working
Medium. After centrifugation of cells at room temperature
(20°C) at 357 g for 2 min, the supernatant was aspirated
and the pellet re-suspended in 5 mL of the HepaRG™
Thaw, Plate, & General Purpose Working Medium. The
viability of the HepaRG™ was estimated to be greater
than 85% using trypan blue exclusion test.
Concentrations of 10, 20, 40, 60, 80, and 100 μM of
mephedrone and MXE were used for metabolism studies
using HepaRG™. For each concentration, the metabolic
profile was studied at 0 time, 90min and 24 h. Previously
prepared HepaRG™ cells were seeded onto central wells
of collagen-coated 96-well plates at a density of 50 ×
103 cells/well in HepaRG™ Thaw, Plate, & General
Purpose Working Medium (50 μL cell solution topped up
to 200 μL media). After 6 h, the media were renewed with
20 μL 10× master solution of each drug concentration and
topped up to 200 μL HepaRG™ Tox Medium Supplement.
Two wells were spared as blank which were topped up to
200 μL HepaRG™ ToxMedium Supplement media; and for
zero times sample, 20 μL of each drug concentration was
topped up to 200 μL HepaRG™ Tox Medium Supplement
media.
The final 200 μL resultant aqueous mixture was
extracted using 400 μL ethyl acetate and then centrifuged
at 3,500 rpm for 10min. Organic layer was moved into a
clean glass vial via a pipette and then evaporated to dryness
using a sample concentrator under streaming N2, reconsti-
tuted with 50 μL acetonitrile, and BSTFA was added in
excess to the mixture warmed in water bath at 50°C for
10min to enhance the derivatization reaction before the
samples were then injected into GC-MS (Perkin Elmer, USA).
The GC-MS components were from Perkin Elmer
(USA). GC model Clarus 600 equipped with an auto sam-
pler and MS model Clarus 600 operated with TurboMass
6.4.2 (Perkin Elmer, USA, 2008). Standards and samples
were run on an Agilent Technologies DB-1 MS column
(30m × 0.25mm × 0.25 μm). Oven temperature programme
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was as following: 150°C for 4min increasing at 25°C/min
to a final temperature of 350°C. Injector port temperature
was held at 250°C. The carrier gas was helium at 1 mL/min
and the injection volume was 1 μL. The transfer line tem-
perature was held at 280°C. Positive ionization was
achieved using an electron impact source at 200°C with
electron energy of 70 eV and the multiplier was set to
300 V. The peaks were observed in total ion count after a
3-min solvent delay. The scan range was 45–320m/z with
a scan time of 0.5 s and an inter-scan delay of 0.01 s.
Electronic balance was from Sartorius (Germany),
GPE-scientific Teflon mortar & pestle (UK), ultrasonic
bath was from Kerry (UK). Shaking water bath was from
Grant Instruments (UK), and a sample concentrator model
was DRI-BLOCK®, DB.3A from TECHNE (UK), which were
used for sample preparation.
2.5 Using HepaRG™ for MTT reduction
studies – Cytotoxicity
Previously prepared HepaRG™ cells were seeded onto
central wells of collagen-coated 96-well plates at a den-
sity of 100 × 103 cells/well in HepaRG™ Thaw, Plate, &
General Purpose Working Medium (50 μL cell solution
topped up to 200 μL media). Two wells were spared as
blank control, and the peripheral wells were filled with
sterile water to prevent media evaporation. The 96-well
plate was incubated at 37°C in a humidified atmosphere
with 5%/95% CO2/ambient atmosphere and 100% rela-
tive humidity for cell adhesion. After 6 h, the medium
was renewed; and on day 1 and day 4, the medium was
replaced with HepaRG™ Tox medium and incubated
under the same conditions, while observing the cell
morphology at the time of replacing the media, the
methylthiazolyldiphenyl-tetrazolium bromide test (MTT)
reduction assay experiments were carried on day 7 with
freshly prepared test drugs. On day 7 after cell seeding,
the HepaRG™ Tox medium was renewed and the cells
were incubated for 48 h with different concentrations of
mephedrone and MXE at 37°C, in a humidified atmo-
sphere with 5%/95% CO2/ambient atmosphere and
100% relative humidity. Those drug concentrations
were freshly prepared from the master stock concentra-
tion in HepaRG™ Tox medium. Each individual plate
included two replicates of blank controls (just media)
and two replicates of negative control (full cell and media
with no test agents). After the 48-h incubation period, the
incubation medium was aspirated, and the attached cells
were washed one time, followed by the addition of fresh
HepaRG™ Tox medium containing 0.5mg/L MTT. The
cells were re-incubated at 37°C in a humidified atmo-
sphere with 5%/95% CO2/ambient atmosphere and
100% relative humidity for 3 h. After aspirating the
medium, the formed insoluble crystals were dissolved
in 100% dimethyl sulfoxide (DMSO). A multiwell plate
reader was used to run the spectrophotometric analysis
at 570 nm wavelength.
For each drug, a range of concentrations from 4 ×
10−2 to 16 mM was tested, each in three independent
experiments. The mean absorbance of the triplicate
experiments for each drug concentration on each occa-
sion was expressed as a percentage of the mean absor-
bance of the control wells.
2.6 Ethical standards
We declare that the presented work complies with the
current British law and ethical standards. This article
does not contain any studies with human participants
or live animals performed by any of the authors. The
pigs were slaughtered in the abattoir and sold for food
consumption. Consequently, the results presented in this
work are not linked to animal testing. All procedures
were ethically approved and risks assessed by the ethics
committee of the University of Lincoln.
3 Results
3.1 Study with pig liver microsomes using
LC-MS
Initially, LC-MS was used for all studies of pig liver
microsomes to determine the possible metabolites.
Mephedrone was incubated with an in-house prepared
pig liver microsomes under the specified conditions and
after termination of the metabolic process samples were
centrifuged, filtered, and injected onto the LC-MS system.
In this study, two metabolites, namely, hydroxytoly-
mephedrone produced by hydroxylation of the methyl
group attached to the aromatic ring, and nor-dihydro
mephedrone produced by a two-step N-demethylation
and reduction of the ketone moiety were monitored as
illustrated in Figure 1. The proposed structures of the
detected metabolites were determined from the fragments
present in the respective mass spectra and according
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to the general known routes (shown in Figure 1 top).
Negative controls were used to verify the absence of these
metabolites in the absence of these drugs. As seen in
Figure 1 (bottom), the suggested metabolic pathway
provides different routes to detoxification by making
the molecules more soluble: using hydroxylation to pro-
duce hydroxytoly-mephedrone, by reducing the carbonyl
group to an alcohol and N-demethylation to modify or
Figure 1: Suggested phase I metabolic pathway of mephedrone adapted from published data for the metabolism of mephedrone and similar
drugs (top). A proposed present metabolic pathway through the identified metabolites of mephedrone utilizing LC-MS (bottom):
(1) mephedrone, (2) hydroxytoly-mephedrone, (3) nor-dihydro mephedrone, and (*) undetected intermediates.
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reduce the hydrophobicity by eliminating methyl groups
from the molecule.
Spectra of the identified metabolites of mephedrone
are illustrated in Figure 2. Figure 2a shows the character-
istic masses for mephedrone (m/z 177, 160) confirming
the presence in the metabolic pool. As seen in Figure 1,
one suggested metabolite is hydroxytoly-mephedrone, in
which two characteristic ions (m/z 160, 177) can be seen
in the mass spectra of Figure 2b, confirming its presence.
Figure 2c also shows the characteristic mass (m/z 166) for
the N-demethylation to produce nor-dihydro mephedrone.
Many of the masses and processes imply a loss of water as
seen in Figure 2.
In a similar way to that performed for mephedrone,
two metabolites were identified for MXE using the animal
model: one metabolite formed by O-demethylation and
the other metabolite formed by the reduction of the ketone
moiety to the corresponding alcohol, confirming the meta-
bolic routes for MXE already found in the literature for
some of the metabolites (Figure 3a). The reported meta-
bolic pathway of ketamine (for comparison and reference)
and the proposed one for MXE are illustrated in Figure 3a
and b, respectively. Apart from the differences in chemical
structure because of the presence of Cl and a shorter alkyl
group in the amine group in ketamine, the rest of the
molecule is very similar. A metabolic pathway can be
expected with similar processes (but not identical) for
both drugs. In our study, dihydro-MXE (Figure 3c, com-
pound 2) and nor-MXE (Figure 3c, compound 3) confirmed
our hypothesis (note the loss of the methyl group occurs
differently through O-demethylation and N-demethylation).
The mass spectra of MXE and the produced metabo-
lites are illustrated in Figure 4. Figure 4a shows the char-
acteristic masses for MXE (m/z 247, 203 and 175) with
some typical fragmentation indicated in the figure. As
for Figure 3, one of the suggested metabolites was nor-
MXE, produced by O-methylation, which had three char-
acteristic ions (m/z 233, 189 and 161) in the metabolic pool
as shown in Figure 4b. Figure 4c also shows the charac-
teristic masses (m/z 249, 205) for the reduction of MXE to
produce dihydro-MXE as suggested in Figure 3c.
3.2 Study of HepaRG™ human cell line
using GC-MS
It is necessary to compare the metabolism obtained
through animal studies with in vitro human studies to
confirm whether the metabolic routes are similar. A
new peak was identified by studying the chromatograms
of mephedrone after incubation with human HepaRG™
cell lines (Figure 5). The fragmentation pattern may
suggest that the new peak is related to the parent drug
and related to methcathinones, with structural change
affecting the amine group. N-demethylation is a likely
pathway for metabolism of mephedrone to produce this
metabolite, which was found to be nor-dihydro mephe-
drone in the previous pig liver microsome study using
LC-MS (Figure 2). The fragmentation pattern is shown
in Figure 5b and shows the fragments from the peak
observed at 6.24 min are compatible with a cathinone.
However, due to the higher fragmentation achieved in
the GC-MS it was not possible to identify either the mole-
cular mass (m/z 165) or the MH+ for nor-dihydro mephe-
drone. However, given the fact that the mephedrone
molecule was identified at a different retention time, as
shown in Figure 5a, we need to speculate this new peak is
one of the expected metabolites.
In comparison, MXE showed no reliable peaks corre-
sponding to the reported metabolites after incubation
with HepaRG™ and GC-MS analysis.
3.3 Study with pooled human hepatocytes
In another study, mephedrone showed a continuous
decrease in drug concentration with HepaRG™ cell lines
over time, while MXE showed a sharp decrease in drug
concentration followed by an increase.
For mephedrone, the drug concentrations relative to
the primary drug concentration dropped to an average of
37% (32–44%) after 90min of incubation with HepaRG™
and then there was another decrease down to an average
of 12% (9–18%) after 24 h. In comparison, drug concen-
trations relative to the primary drug concentration for
MXE dropped to an average of 52% (45−58%) after 90min
of incubation, but then it increased to an average of 74%
(64–84%) after 24 h (Figure 6). This sudden increase might
be related to cellular apoptosis and the breaking of the
cellular membrane releasing all the internal contents of
unchanged drug.
3.4 Cell death studies for mephedrone
and MXE
For cytotoxicity study using HepaRG™ cells, the data
were collected from three independent experiments using
11 different concentrations of each drug in the range of
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4 × 10−2 to 16 mM. The collected data, i.e. about the per-
centage of cell death, were normalized, where the blanks
were considered as having zero percentage cell death.
The potency of the drug to cause the effect is evaluated
Figure 2: LC-MS data of (a) mephedrone and (b) a metabolite produced by in vitro metabolism of mephedrone, in the hydroxylation step:
hydroxytoly-mephedrone. It also presents (c) a metabolite produced by a two-step process of reduction and demethylation: nor-
dihydromephedrone.
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by EC50 value, which is defined as “the concentration of
the agonist required to provoke a response halfway
between the baseline and maximal response” [29]. In
the current part of the work, the agonist is one of the
Figure 3: (a) Suggested phase I metabolic pathway for MXE (extrapolated from published data), (b) metabolic pathway of ketamine, and
(c) the present proposed metabolic pathway of MXE, where (1) represents MXE, (2) dihydro-MXE, and (3) nor-MXE.
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selected NPSs and the provoked response is the percen-
tage of cell death.
The collected data were plotted as percentage of cell
death normalized to maximum response versus concen-
tration, and the resultant normalized data were analysed
using curve fitting with non-linear regression best-fit
approach using GraphPad Prism version 6.00 for Windows,
GraphPad Software, La Jolla California USA. The graph for
all drugs showed increase in the response with increasing
concentration (Figure 6).
All tested and selected NPSs showed reproducible
response that is dependent on concentration, where
increasing the concentration increases the percentage
of cell death. Within the concentration range used,
mephedrone and MXE showed nearly similar average
maximal percentage cell death of about 84% and 78%,
respectively. Under the specified condition (see materials
and methods) and within the specified concentration
range (4 × 10−2 to 16 mM), MXE showed the most potent
effect with an EC50 value of 0.3211 mM (79 μg/mL). For
4-methyl methcathinone, the EC50 value was 0.6297 mM
(111 μg/mL; Figure 7).
The calculated molarity values were converted into
the equivalent SI to compare with the available reported
toxic values through in vitro, post-mortem, or clinical
samples. Equivalent concentrations were 111 μg/mL and
79 μg/mL for mephedrone and MXE, respectively (Table 1).
4 Discussion
4.1 Study of pig liver microsomes
For mephedrone, a previous study of the in vivo metabo-
lism suggested a phase I metabolic pathway, whereby the
drug is metabolized by one or more steps of hydroxyla-
tion, demethylation, and reduction [12]. This study iden-
tified two main metabolites, hydroxytoly-mephedrone
and nor-dihydro mephedrone, being consistent with the
previously identified metabolites for mephedrone in
urine [10], and the general metabolic pathways of cath-
inone derivatives [30]. Meyer et al. [12] concluded that
phase II metabolic pathways are also involved in the
metabolism of mephedrone through sulphonation or glu-
curonidation of the hydroxytoly-mephedrone and its
demethylated form. The results presented in Figure 1 con-
firmed these findings and reaffirmed the previously
reported metabolic pathway but also confirmed the
validity of our metabolic system for the production of
metabolites.
Similarly, the metabolites observed for MXE in our
study is similar to other published data and metabolic
studies previously published for ketamine [24]. As MXE
can be structurally related to ketamine, a similar
Figure 4: LC-MS data. (a) Mass spectra information for MXE with
characteristic m/z ratios for the molecule at 247, 203, and 175;
(b) mass spectra information for nor-MXE produced by
O-demethylation with characteristicm/z ratios at 161, 189, and 233;
and (c) dihydro-MXE produced by reduction of the ketone moiety
with characteristic m/z ratios at 205 and 249.
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metabolic strategy for demethylation can be suggested to
explain the way the body may eliminate these drugs.
Ketamine is metabolized through N-dealkylation to nor-
ketamine followed by the hydroxylation of norketamine
Figure 5: Sample chromatogram (a) and mass spectra (b) peak appearing at 6.24min from samples of mephedrone after incubation with
HepaRG™ compared to mephedrone.
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at different locations and the formation of 5,6-dehydro-
norketamine. In the case of ketamine, the same metabo-
lites are observed in vitro as well as in vivo in humans and
animals [31,32]. This highly suggests that chemically
related drugs might use the same enzymatic systems in
humans and animals. Meyer et al. [12] utilized GC-MS for
in vivo studies and detection of MXE metabolites in
human and rat urine. They concluded that MXE may be
metabolized through phase I and phase II enzymatic sys-
tems. Phase I enzymatic reactions involve N-demethyla-
tion, O-demethylation, and hydroxylation or a combination
of these metabolic steps. It was concluded through their
study also that phase II metabolic pathways are involved
in the metabolism of MXE through sulphonation or
glucuronidation of most of these metabolites [19]. In
Menzies et al. [24], different phase I and II metabolites
were identified, including the O-demethylation of MXE
described here. However, in this study, not all metabo-
lites could be detected in vitro and the metabolite
formed by reduction, dihydro-MXE, was not described.
This metabolite, to our knowledge, has not yet been
described in the literature.
In our study, LC-MS analysis was used to determine
which metabolite may be present in the metabolic studies
and to determine whether any of these could be identified
using GC-MS analysis. For both drugs, metabolites of
the demethylation pathway were identified by LC-MS;
and due to their chemical nature, they are more likely
to be also identified by GC-MS. As for the hydroxylation
pathway, these metabolites are likely to be not too vola-
tile and polar and less likely to be identified by GC-MS
analysis, even with the aid of derivatization. Therefore,
the HepaRG™ cell study focused on the demethylation
pathway for GC-MS analysis.
4.2 Study with HepaRG™ human cell line
Since the previous study of mephedrone using LC-MS
showed the presence of both hydroxytoly-mephedrone
Figure 6: Relative drug concentrations of selected NPS to the pri-
mary drug concentration after 90min and 24 h of incubation with
HepaRG™. Top: mephedrone. Bottom: methoxetamine.
Figure 7: Normalized cell death percentage of HepaRG cells induced
by selected NPS 48 h after incubation under specified conditions.
Top: mephedrone. Bottom: methoxetamine.
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and nor-dihydro mephedrone as metabolites, it was
logical to assume that only nor-dihydro mephedrone or
other metabolites produced by demethylation is likely to
be detected in the HepaRG™ study using GC-MS, as these
compounds are the result of at least one step of N-
demethylation and may therefore be volatile enough
with the help of derivatization to be visible in GC-MS.
Hydroxytoly-mephedrone is the result of hydroxylation
and therefore is too polar to be analysed in a GC-MS
even with the aid of derivatization. GC-MS was chosen
as the analytical technique as it is more common in for-
ensic laboratories, and we aimed to demonstrate the
potential versatility of this technique for the identifica-
tion of novel metabolites in human cell lines. The
demethylated metabolite was detected for mephedrone
using HepaRG™ human cell line and GC-MS after deri-
vatization as shown in Figure 5.
The absence of these demethylated compounds, not
detected for MXE in GC-MS, should not be interpreted as
they were not produced in the metabolic system. Instead,
it should be interpreted that these metabolites were not
volatile enough for detection using GC-MS even with
BSTFA derivatization as MXE is already a fairly polar
compound, even before metabolism takes place. This
may be of interest to forensic laboratories, where some-
times the presence of metabolites is used to confirm the
intake of a specific drug. For MXE, this information may
not be applicable when using only GC-MS of biological
samples, whereas mephedrone’s metabolite is detectable.
4.3 Pooled human hepatocytes
The structural difference in mephedrone and MXE may
explain their differences in physicochemical properties,
which explains why these drugs behaved differently in
biological systems in terms of, for example, transcellular
transport, protein affinity, and metabolism. Protein
binding is one of the major components that may affect
drug’s efficacy, as it is only the free unbound fraction of
the drug that is available to be transported to the intracel-
lular space for further biological action, e.g. metabolism.
For both drugs, mephedrone and MXE, a decrease in
the concentration of the parent drug in the incubation
media is observed with time. This can be associated
with the intake by the cell. In both cases, the intake after
90min is around 70% for mephedrone (leaving 30% in
the media) and 55% for MXE (leaving 45% in the media).
In the case of mephedrone, this intake continues up to
24 h and later with an absorption of nearly 90%.
However, the observed increase in MXE concentration
after 24 h of incubation following the sharp decrease after
90min could be due to cell death and some lysis, which
may cause some of the intracellular content of MXE to
pool into the extracellular space. This general trend of
lower available extracellular drug concentration is a
strong evidence that drugs are being used or consumed
by the cells, most likely through metabolism. Nearly
60–80% (depending on the concentration) is found
back in the media, which approximates well to the per-
centage of cell death produced by MXE. This would sug-
gest that most of the cells dying suffered a process of
lyses when treated with MXE in contrast with the beha-
viour observed in mephedrone where the cellular wall
remained intact after death (in the period of our study:
24 h).
4.4 Cell death
Mephedrone is an amphetamine-related drug with little
data available about its cytotoxic effects. However,
amphetamines, cathinones, and related drugs have
been studied, both in vitro and in vivo. Cytotoxicity
caused by amphetamines mainly affects the liver, the
organ most at risk in general for drug-related toxicity
and specifically amphetamines [33]. No similar data are
available for MXE, the ketamine analogue belonging to
the arylcyclohexylamine, or other drugs of the same
class, for comparison.
Table 1: MTT of selected NPS summary: mephedrone and MXE
Drug Max cell deatha (%) EC50b (mM) Equivalent (μg/mL) Reported toxic (μg/mL)c
Mephedrone 84 0.6297 111.0 0.5–22
MXE 78 0.3211 79.00 NA
aMax death cell induced under the specified condition and within the specified range (4 × 10−2 to 1.6 × 101 mM). bEC50 is the concentration
required to cause cell death a halfway between the baseline and maximal response. cReported toxic values through in vivo, post-mortem, or
clinical samples.
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Compared to the published data about cell death
cytotoxic effect and other cytotoxic effects, the reported
EC50 values in our study for mephedrone, 0.3211 mM, are
lower than the reported EC50 for amphetamines, cathi-
nones, and related drugs in in vitro studies, where the
EC50 values ranged between 0.74 and 5.26 mM [28]. The
values for EC50 obtained in the case of mexothetamine
were calculated as 0.6297 mM. In this case, no literature
data on MXE or related drugs for in vitro EC50 values are
available for comparison.
The obtained EC50 values in this part of the work are
many folds higher than the reported toxic peak concen-
tration in either clinical-intoxicated patients’ samples
or post-mortem samples. The reported concentration of
mephedrone, as an example, in post-mortem biological
samples in four fatalities in Scotland, ranged between
0.50 and 22 μg/mL [29]. The obtained EC50 value of
0.6297 mM for mephedrone, which is equivalent to
111 μg/mL, is about 5–22 times more than the reported
values in biological samples. In fact, it has been reported
that the tissue levels of amphetamine-related drugs can
be up to 18–30 times higher than the blood concentra-
tions. This discrepancy between in vitro and in vivo data,
in case of amphetamines and related drugs, is partially
due to their low protein-binding affinity, which makes
their diffusion from plasma into tissues more favourable.
In addition, post-mortem samples are often from victims
who have received emergency care in their pre-mortem
intoxicated interval [34].
None of the selected NPS yielded 100% cell death.
However, mephedrone and MXE caused at least the death
of 73–84% of the cells. The limitations to this study are
based on the response of the cells under these specific
stress conditions. Other cytotoxic effects need to be
explored to elaborate about the toxic effects of NPS in
general.
5 Conclusion
The laboratory prepared pig liver microsomes were used
as the animal model, and the results of the metabolism
were tracked using an LC-MS as separation and identifi-
cation technique. In the case of mephedrone and MXE,
it would suggest that these drugs have similar (not iden-
tical) metabolic pathways to transfer them to more
soluble compounds. Two metabolites, namely, dihydro-
MXE and nor-MXE, for MXE are presented in this study,
produced by O-demethylation and by the reduction of the
ketone moiety, where, to the best of our knowledge, the
presence of none of these metabolites has been pre-
viously suggested in literature.
When looking at in vitro studies using the human
HepaRG™ cells, only the demethylation pathway for
mephedrone could be confirmed using GC-MS. GC-MS
was employed to illustrate the facilities that may be avail-
able at commercial laboratories. However, due to this, it
should be noted that the other metabolites previously
described may not be detectable. Yet, GC-MS was able
to identify a metabolite for mephedrone, which could in
turn help law enforcement and emergency services with
the identification of suspected ingestion of this NPS. This
point has also been proven by other authors as com-
mented in the introduction.
In terms of cytotoxicity in vitro EC50 values for
mephedrone and MXE were reported for the first time.
These values for mephedrone and MXE were 0.3211 and
0.6297 mM, respectively.
Considering the limitations, the in vitro study of the
metabolism of the designer drugs is a promising
approach for the prediction of the toxicological and clin-
ical profile of the newly emerging drugs in the early
stages of their appearance in the market and could be
used as a preliminary step before developing analytical
methods for the study of designer drugs and their
metabolites.
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